[go: up one dir, main page]

WO2024129040A1 - A card test for the hallucinogenic psilocybin molecule that allows the diagnosis of toxic mushrooms and mushroom toxicities - Google Patents

A card test for the hallucinogenic psilocybin molecule that allows the diagnosis of toxic mushrooms and mushroom toxicities Download PDF

Info

Publication number
WO2024129040A1
WO2024129040A1 PCT/TR2023/051529 TR2023051529W WO2024129040A1 WO 2024129040 A1 WO2024129040 A1 WO 2024129040A1 TR 2023051529 W TR2023051529 W TR 2023051529W WO 2024129040 A1 WO2024129040 A1 WO 2024129040A1
Authority
WO
WIPO (PCT)
Prior art keywords
analyte
psilocybin
test
molecule
antibody
Prior art date
Application number
PCT/TR2023/051529
Other languages
French (fr)
Inventor
Ilgaz AKATA
Ertugrul KAYA
Original Assignee
T.C Ankara Universitesi Rektorlugu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2022/019556 external-priority patent/TR2022019556A2/en
Application filed by T.C Ankara Universitesi Rektorlugu filed Critical T.C Ankara Universitesi Rektorlugu
Publication of WO2024129040A1 publication Critical patent/WO2024129040A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine

Definitions

  • the invention falls within the technical field of biochemistry and relates to an immunochromatographic card test for the diagnosis of the psilocybin molecule, which allows the diagnosis of toxic mushrooms and mushroom toxicities and has a hallucinogenic effect on the brain.
  • the invention essentially relates to a card test that allows the diagnosis of toxic mushrooms and mushroom toxicity and is more economical than current applications and requires less expertise and shorter periods of time, for the diagnosis of the psilocybin molecule, which has a hallucinogenic effect on the brain.
  • the invention relates to a method of performing the immunochromatographic card test for the diagnosis of the psilocybin molecule, which allows the diagnosis of toxic mushrooms and mushroom toxicities and has a hallucinogenic effect on the brain.
  • the hallucinogenic effects of psilocybin-containing mushrooms have been known for 2000 years. In particular, it is known that the Mayans and Aztecs, the civilizations of the South American region, used these mushrooms. Its chemical formula is N,N-dimethyl-4- phosphoryloxytryptamine.
  • the Psilocybin molecule is known to be present in the fungus species Psilocybe cubensis, Psilocybe argentipes, Psilocybe mexicana, Psilocybe bohemica, Panaeolus cyanoscens, Panaeolus foenisecii, Gymnophilus purpuratus, Stropharia semiglobata. Apart from these species, this molecule can also be found in some other fungus species. As is known in the art, it is known to cause LSD-type hallucinations. Its chemical structure is provided as Formula 1.
  • Toxicities are especially seen in autumn and spring, during which mushrooms grow intensively. Despite all the developments in modern medicine, no definitively effective medicine has been found for the treatment of certain mushroom toxicities.
  • the main toxins present in mushrooms are Cyclopeptides (Amanitins, phallotoxins, virotoxins) (Hepatotoxic); Giromitrin (Monomethylhydrazine) (NephroHepato-Neurotoxic); Orellanin (Nephrotoxic); Muscarine (Muscarinic effect, Autonomic Nervous system); Ibotenic acid and Muskimol (Hallucinogenic); Coprin (Disulfiram-like effect) and Psilocybin (Hallucinogenic).
  • the invention relates to a card test for the detection of toxicity and/or hallucinogenic cases caused by a toxic substance, psilocybin molecule, contained in the mushroom.
  • the invention offers a test method which is less costly and does not require well- equipped equipment, therefore eliminates the need for qualified personnel and provides rapid results by an antibody-antigen interaction using an antibody suitable for the detection of toxicity and/or hallucinogenic cases caused by a toxic substance, psilocybin molecule, contained in the mushroom.
  • the invention relates to an immunochromatographic card test for detecting the presence of psilocybin molecules, which allows the diagnosis of toxic mushrooms and mushroom toxicities, which test comprises o at least one test line containing psilocybin molecules immobilised to the membrane, o an analyte for the determination of antibody-antigen interaction, o a conjugate pad to which monoclonal antibodies specific to said analyte are added, wherein said antibodies include mouse immunoglobulin G monoclonal antibodies, and which is based on a principle of single line (positive)-double line (negative) by moving towards the test line after the interaction of the analyte and antibodies and then competing with the psilocybin molecule immobilised to the membrane.
  • said membrane is based on nitrocellulose.
  • the invention also relates to an in-vitro method for detecting the presence of the psilocybin molecule, which allows the diagnosis of toxic mushrooms and mushroom toxicities.
  • the method of the invention includes the following process steps:
  • said monoclonal antibody includes mouse immunoglobulin G monoclonal antibodies
  • test line if the test line is single, then analyzing the test as positive.
  • the invention also relates to an immunochromatographic card test for detecting the presence of psilocybin, which allows the diagnosis of toxic mushrooms and mushroom toxicities, which comprises
  • said colored monoclonal antibody includes mouse immunoglobulin G monoclonal antibodies
  • test line containing specific monoclonal antibodies and which is based on the principle that the analyte selectively binds to the specific colored antibody thereof on the conjugate pad, a complex of the analyte-antibody-color molecule moves towards the test line together with the analyte, and then a visible colored line is formed in the test line area.
  • the invention also relates to an in-vitro method for detecting the presence of the psilocybin molecule, which allows the diagnosis of toxic mushrooms and mushroom toxicities.
  • the method of the invention includes the following process steps:
  • said colored monoclonal antibody includes mouse immunoglobulin G monoclonal antibodies
  • the subject matter of the invention falls within the technical field of biochemistry and relates to a card test for the diagnosis of the psilocybin molecule, which allows the diagnosis of toxic mushrooms and mushroom toxicities and has a hallucinogenic effect on the brain, but is described with examples only for a better understanding of the subject in a non-limiting sense.
  • the basic working principle of the card test of the invention is based on an immunochromatographic method.
  • the test card of the invention includes at least one sample pad, a conjugate pad, at least one membrane, at least one test line, at least one control line, at least one absorbent pad, and/or at least one plastic base.
  • the elements given here are the basic components of immunochromatographic tests, and changes may occur in the number or functions of the elements for a high-efficiency diagnosis due to the advancement of the technology. As mentioned, the present inventors may keep up with the changes in immunochromatographic cards and make changes in the number and functions of the components in the card test.
  • the protection scope of the invention is independent of the elements included in the card test based on the immunochromatographic test method.
  • the protection scope of the invention is essentially based on the fact that there is no need for less costly and well-equipped equipment and thus no qualified personnel is required and the rapid results are obtained, by means of the immunochromatographic method based on an antibody-antigen interaction for the diagnosis of the psilocybin molecule, which previously required the presence of the expensive devices, qualified personnel and well-equipped laboratories.
  • the sample pad in the card test of the invention is used to drop the liquid material to be analyzed and keeps the dropped liquid.
  • the liquid material to be analyzed may be, but is not limited to, the juice of the mushroom, or the serum of the poisoned patient.
  • the conjugate pad in the card test of the invention contains psilocybin-specific antibodies marked and colored with gold nanoparticles.
  • the sample liquid passes over this pad and drags the colored antibodies on the pad.
  • Psilocybin-specific antibodies are specific to this invention and are produced by the inventors.
  • the psilocybin molecules are injected into the experimental mice, the mice are treated with a series of immunogens, and after a while, the B lymphocytes in the spleens of the mice are collected and the cells that produce antibodies specific to psilocybin are isolated.
  • the monoclonal psilocybin antibodies produced by these cells are used as reported in the invention. Consequently, specific antibodies to the psilocybin molecule have been produced specifically for this invention and are psilocybin-specific mouse IgG type monoclonal antibodies.
  • the membrane in the card test of the invention is used to move the liquid sample towards the test line by the effect of capillary flow. Different membranes may be used for this purpose, but nitrocellulose membrane is often used.
  • the sample test line contains membrane-immobilised psilocybin molecules if it is to be produced in a competitive model. The quantity of these molecules is adjusted according to the desired threshold value during R&D studies. If the test is to be produced in a sandwich model, then the psilocybin-specific antibodies are immobilised to the test line.
  • the sample should move down to the control line in the card test of the invention, otherwise the test will be considered invalid.
  • the anti-antibodies are immobilised on the membrane on this line.
  • the absorbent pad in the card test of the invention is placed at the endmost point and is responsible for retaining the excess of the liquid sample. When a large amount of liquid sample is dropped into the test, it accumulates in the pad and contributes to the correct functioning of the test.
  • the card test of the present invention may function with two types of working principles. Accordingly,
  • the operation method of the card test is as follows:
  • the analyte in the sample selectively binds to the colored specific antibody on the conjugate pad, and the complex of the analyte-antibody-color molecule moves towards the test line along with the sample.
  • the analyte in the complex arrived at the test line together with the sample binds to the antibodies immobilised to the test line and causes a colored visible line in the test line area. As a color will appear on the control line in every case where the test is valid, a double line will be seen in the observation window as a positive result of the sandwich model. If the analyte sought is not found, the result of the test is expected to be negative. As there is no analyte in the sample, there is no binding to the colored antibody on the conjugate pad.
  • the operation method of the card test is as follows:
  • a specific monoclonal antibody is added to the analyte colored by binding a color molecule on the conjugate pad. These antibodies are not immobile, and these colored antibodies are draft towards the test line with the incoming liquid sample.
  • the analyte to be analyzed is immobilised to the test line area.
  • the result is positive if a single line is seen in the observation window, and the result is negative if a double line is observed. Due to this feature, the models described give contradictory results, and care should be taken during a practical application. If the analyte sought is found in the sample, the result of the test is expected to be negative (double line).
  • the technical innovation for which the invention claims an essential protection and provides for the relevant technical field is the introduction of the use of the immunochromatographic methods based on an antibody-antigen interaction for the diagnosis of the hallucinogenic psilocybin molecule contained in the mushroom.
  • specially produced monoclonal antibody molecules are used as antibodies that will specifically interact with the psilocybin molecule as an antigen.
  • the antibodyantigen complex is a highly selective binding, the molecule desired to be analyzed may be successfully detected.
  • Said antibody molecule is a special molecule which selectively recognizes the analyte. Due to a high antibody-antigen selectivity ratio, the diagnostic reliability of the card tests of the invention is quite high.
  • the card test which makes this interaction possible thanks to the antibody-antigen selective relationship, will provide reliable test results by providing a high diagnosis rate without requiring an equipped laboratory and qualified personnel.
  • the card test of the invention has a simple structure without requiring high equipment for the diagnosis of the psilocybin molecule in mushrooms in the present art. Therefore, as the production costs will be low, sales will also be economical. In this way, it will be possible to obtain a diagnostic product at affordable prices that many people associated with the mushroom habitat may easily obtain.
  • the card test of the present invention allows the test results to be obtained in a short time.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention relates to a card test that allows the diagnosis of toxic mushrooms and mushroom toxicities and is more economical than current applications and requires less expertise and shorter periods of time, for the diagnosis of the psilocybin molecule, which has a hallucinogenic effect on the brain.

Description

A CARD TEST FOR THE HALLUCINOGENIC PSILOCYBIN MOLECULE THAT ALLOWS THE DIAGNOSIS OF TOXIC MUSHROOMS AND MUSHROOM TOXICITIES
TECHNICAL FIELD
The invention falls within the technical field of biochemistry and relates to an immunochromatographic card test for the diagnosis of the psilocybin molecule, which allows the diagnosis of toxic mushrooms and mushroom toxicities and has a hallucinogenic effect on the brain.
The invention essentially relates to a card test that allows the diagnosis of toxic mushrooms and mushroom toxicity and is more economical than current applications and requires less expertise and shorter periods of time, for the diagnosis of the psilocybin molecule, which has a hallucinogenic effect on the brain.
In another aspect, the invention relates to a method of performing the immunochromatographic card test for the diagnosis of the psilocybin molecule, which allows the diagnosis of toxic mushrooms and mushroom toxicities and has a hallucinogenic effect on the brain.
PRIOR ART
The hallucinogenic effects of psilocybin-containing mushrooms have been known for 2000 years. In particular, it is known that the Mayans and Aztecs, the civilizations of the South American region, used these mushrooms. Its chemical formula is N,N-dimethyl-4- phosphoryloxytryptamine. The Psilocybin molecule is known to be present in the fungus species Psilocybe cubensis, Psilocybe argentipes, Psilocybe mexicana, Psilocybe bohemica, Panaeolus cyanoscens, Panaeolus foenisecii, Gymnophilus purpuratus, Stropharia semiglobata. Apart from these species, this molecule can also be found in some other fungus species. As is known in the art, it is known to cause LSD-type hallucinations. Its chemical structure is provided as Formula 1.
Figure imgf000003_0001
Formula 1 .
In many parts of our country, especially in rural areas, people collect mushrooms and consume them as food. It seems that mushrooms are consumed by people as they contain protein, are free, and are delicious. In our country, deaths may occur when mushrooms picked by mushroom pickers who do not have sufficient knowledge are consumed as food. Also, cases of poisoning have been reported due to erroneous beliefs that mushrooms are not toxic. Toxic varieties of mushrooms may grow among non-toxic mushrooms in nature, or they can resemble non-toxic mushrooms. Therefore, the discrimination of mushrooms should be done by an expert.
Toxicities are especially seen in autumn and spring, during which mushrooms grow intensively. Despite all the developments in modern medicine, no definitively effective medicine has been found for the treatment of certain mushroom toxicities. The main toxins present in mushrooms are Cyclopeptides (Amanitins, phallotoxins, virotoxins) (Hepatotoxic); Giromitrin (Monomethylhydrazine) (NephroHepato-Neurotoxic); Orellanin (Nephrotoxic); Muscarine (Muscarinic effect, Autonomic Nervous system); Ibotenic acid and Muskimol (Hallucinogenic); Coprin (Disulfiram-like effect) and Psilocybin (Hallucinogenic).
In the art, the diagnosis of psilocybin, which is known as the toxic substance contained in mushrooms and has a hallucinogenic effect, is carried out by thin layer chromatography, HPLC, LC-MS/MS, GC-MS and radioimmunoassay methods. As it is known, these methods requires expensive devices, qualified personnel and well- equipped laboratories. The maintenance and auxiliary equipment of these devices are also quite expensive, and even their maintenance requires expert personnel. Therefore, especially in cases of toxicity for which a rapid diagnosis is important, it is important to use diagnostic methods that provide faster results, does not require a check by an expert, and have low costs. Consequently, there is a need for test methods that provide rapid results, do not require an expert and are low-cost, for the detection of toxicity cases caused by the psilocybin molecule in order to provide solutions and advantages to the relevant technical field needs.
SUMMARY OF THE INVENTION
As is known in the relevant technical field, there are no test methods for the rapid diagnosis of mushroom toxicity caused by psilocybin molecules contained in mushrooms. In the art, thin layer chromatography, HPLC, LC-MS/MS, GC-MS and radioimmunoassay methods are used to detect these cases. These methods requires expensive devices, qualified personnel and well-equipped laboratories. Contrary to the technical disadvantages mentioned, the present invention offers a diagnostic method that is less costly and does not require well-equipped equipment, thus eliminating the need for qualified personnel and providing rapid results.
The invention relates to a card test for the detection of toxicity and/or hallucinogenic cases caused by a toxic substance, psilocybin molecule, contained in the mushroom.
The invention offers a test method which is less costly and does not require well- equipped equipment, therefore eliminates the need for qualified personnel and provides rapid results by an antibody-antigen interaction using an antibody suitable for the detection of toxicity and/or hallucinogenic cases caused by a toxic substance, psilocybin molecule, contained in the mushroom.
In order to provide all mentioned technical solutions and advantages, the invention relates to an immunochromatographic card test for detecting the presence of psilocybin molecules, which allows the diagnosis of toxic mushrooms and mushroom toxicities, which test comprises o at least one test line containing psilocybin molecules immobilised to the membrane, o an analyte for the determination of antibody-antigen interaction, o a conjugate pad to which monoclonal antibodies specific to said analyte are added, wherein said antibodies include mouse immunoglobulin G monoclonal antibodies, and which is based on a principle of single line (positive)-double line (negative) by moving towards the test line after the interaction of the analyte and antibodies and then competing with the psilocybin molecule immobilised to the membrane.
In a possible embodiment of the invention, said membrane is based on nitrocellulose.
The invention also relates to an in-vitro method for detecting the presence of the psilocybin molecule, which allows the diagnosis of toxic mushrooms and mushroom toxicities. The method of the invention includes the following process steps:
- adding a specific monoclonal antibody to the analyte colored by binding a color molecule on the conjugate pad; wherein said monoclonal antibody includes mouse immunoglobulin G monoclonal antibodies,
- moving the non-stationary antibodies and the analyte which may likely contain antigen together towards at least one psilocybin-containing test line,
- if the test line is single, then analyzing the test as positive.
The invention also relates to an immunochromatographic card test for detecting the presence of psilocybin, which allows the diagnosis of toxic mushrooms and mushroom toxicities, which comprises
- a conjugate pad containing the antibodies specific to the psilocybin molecule, wherein said colored monoclonal antibody includes mouse immunoglobulin G monoclonal antibodies,
- an analyte for the determination of antibody-antigen interaction,
- at least one test line containing specific monoclonal antibodies and which is based on the principle that the analyte selectively binds to the specific colored antibody thereof on the conjugate pad, a complex of the analyte-antibody-color molecule moves towards the test line together with the analyte, and then a visible colored line is formed in the test line area.
The invention also relates to an in-vitro method for detecting the presence of the psilocybin molecule, which allows the diagnosis of toxic mushrooms and mushroom toxicities. The method of the invention includes the following process steps:
- selectively binding the analyte in the sample to the specific colored antibody thereof on the conjugate pad, wherein said colored monoclonal antibody includes mouse immunoglobulin G monoclonal antibodies,
- forming a complex of the analyte-antibody-color molecule by the analyte and antibody, and moving that complex towards the test line, binding the analyte in the complex arrived at the test line together with the sample to antibodies immobilised to the test line, and obtaining a colored visible line in the test line area.
DETAILED DESCRIPTION OF THE INVENTION
In this detailed description, the subject matter of the invention falls within the technical field of biochemistry and relates to a card test for the diagnosis of the psilocybin molecule, which allows the diagnosis of toxic mushrooms and mushroom toxicities and has a hallucinogenic effect on the brain, but is described with examples only for a better understanding of the subject in a non-limiting sense. The basic working principle of the card test of the invention is based on an immunochromatographic method. The test card of the invention includes at least one sample pad, a conjugate pad, at least one membrane, at least one test line, at least one control line, at least one absorbent pad, and/or at least one plastic base. The elements given here are the basic components of immunochromatographic tests, and changes may occur in the number or functions of the elements for a high-efficiency diagnosis due to the advancement of the technology. As mentioned, the present inventors may keep up with the changes in immunochromatographic cards and make changes in the number and functions of the components in the card test. The protection scope of the invention is independent of the elements included in the card test based on the immunochromatographic test method. The protection scope of the invention is essentially based on the fact that there is no need for less costly and well-equipped equipment and thus no qualified personnel is required and the rapid results are obtained, by means of the immunochromatographic method based on an antibody-antigen interaction for the diagnosis of the psilocybin molecule, which previously required the presence of the expensive devices, qualified personnel and well-equipped laboratories.
The sample pad in the card test of the invention is used to drop the liquid material to be analyzed and keeps the dropped liquid. The liquid material to be analyzed may be, but is not limited to, the juice of the mushroom, or the serum of the poisoned patient.
The conjugate pad in the card test of the invention contains psilocybin-specific antibodies marked and colored with gold nanoparticles. The sample liquid passes over this pad and drags the colored antibodies on the pad.
Psilocybin-specific antibodies are specific to this invention and are produced by the inventors. The psilocybin molecules are injected into the experimental mice, the mice are treated with a series of immunogens, and after a while, the B lymphocytes in the spleens of the mice are collected and the cells that produce antibodies specific to psilocybin are isolated. The monoclonal psilocybin antibodies produced by these cells are used as reported in the invention. Consequently, specific antibodies to the psilocybin molecule have been produced specifically for this invention and are psilocybin-specific mouse IgG type monoclonal antibodies. In this way, the antibody and antigen interaction obtained may be achieved specifically, and it will be possible to diagnose the psilocybin molecule by the immunochromatographic method. The membrane in the card test of the invention is used to move the liquid sample towards the test line by the effect of capillary flow. Different membranes may be used for this purpose, but nitrocellulose membrane is often used.
In the card test of the invention, the sample test line contains membrane-immobilised psilocybin molecules if it is to be produced in a competitive model. The quantity of these molecules is adjusted according to the desired threshold value during R&D studies. If the test is to be produced in a sandwich model, then the psilocybin-specific antibodies are immobilised to the test line.
The sample should move down to the control line in the card test of the invention, otherwise the test will be considered invalid. The anti-antibodies are immobilised on the membrane on this line.
The absorbent pad in the card test of the invention is placed at the endmost point and is responsible for retaining the excess of the liquid sample. When a large amount of liquid sample is dropped into the test, it accumulates in the pad and contributes to the correct functioning of the test.
As known in the art, there are two types of card diagnosis methods based on the immunochromatographic method. These are called a competitive model and a sandwich model, and these two methods have their advantages and disadvantages. The card test of the present invention may function with two types of working principles. Accordingly,
If the sandwich method will be used, the operation method of the card test is as follows:
The analyte in the sample selectively binds to the colored specific antibody on the conjugate pad, and the complex of the analyte-antibody-color molecule moves towards the test line along with the sample. The analyte in the complex arrived at the test line together with the sample binds to the antibodies immobilised to the test line and causes a colored visible line in the test line area. As a color will appear on the control line in every case where the test is valid, a double line will be seen in the observation window as a positive result of the sandwich model. If the analyte sought is not found, the result of the test is expected to be negative. As there is no analyte in the sample, there is no binding to the colored antibody on the conjugate pad. When these antibodies drift with the sample and reach the test line area, they do not bind to the immobilised antibodies in the test line and instead, proceed and accumulate on the waste pad. As the waste pad is in a closed area, no colored lines are visible. As a color will appear on the control line in every case where the test is valid, a single line appears in the observation window as a result of the negative result of the sandwich model, and this is the control line.
If the competitive method will be used, the operation method of the card test is as follows:
A specific monoclonal antibody is added to the analyte colored by binding a color molecule on the conjugate pad. These antibodies are not immobile, and these colored antibodies are draft towards the test line with the incoming liquid sample. The analyte to be analyzed is immobilised to the test line area. In the competitive model, the result is positive if a single line is seen in the observation window, and the result is negative if a double line is observed. Due to this feature, the models described give contradictory results, and care should be taken during a practical application. If the analyte sought is found in the sample, the result of the test is expected to be negative (double line).
The technical innovation for which the invention claims an essential protection and provides for the relevant technical field is the introduction of the use of the immunochromatographic methods based on an antibody-antigen interaction for the diagnosis of the hallucinogenic psilocybin molecule contained in the mushroom. In the invention, specially produced monoclonal antibody molecules are used as antibodies that will specifically interact with the psilocybin molecule as an antigen. As the antibodyantigen complex is a highly selective binding, the molecule desired to be analyzed may be successfully detected. Said antibody molecule is a special molecule which selectively recognizes the analyte. Due to a high antibody-antigen selectivity ratio, the diagnostic reliability of the card tests of the invention is quite high. In the present art, it is difficult to detect the psilocybin molecule in toxic mushrooms with high reliability due to the need to apply highly equipped and specialization-required methods. The card test, which makes this interaction possible thanks to the antibody-antigen selective relationship, will provide reliable test results by providing a high diagnosis rate without requiring an equipped laboratory and qualified personnel. The card test of the invention has a simple structure without requiring high equipment for the diagnosis of the psilocybin molecule in mushrooms in the present art. Therefore, as the production costs will be low, sales will also be economical. In this way, it will be possible to obtain a diagnostic product at affordable prices that many people associated with the mushroom habitat may easily obtain.
The card test of the present invention allows the test results to be obtained in a short time.
The scope of protection of the invention is specified in the attached claims and cannot be limited to what is explained in this detailed description for the exemplary purposes. That is because it is clear that a person skilled in the art may represent similar embodiments in the light of what has been explained above without departing from the main spirit of the invention.

Claims

CLAIMS An immunochromatographic card test for detecting the presence of psilocybin molecules, which allows the diagnosis of toxic mushrooms and mushroom toxicities, which comprises o at least one test line containing psilocybin molecules immobilised to the membrane, o an analyte for the determination of antibody-antigen interaction, o a conjugate pad to which monoclonal antibodies specific to said analyte are added, wherein said antibodies include mouse immunoglobulin G monoclonal antibodies, and which is based on a principle of single line (positive)-double line (negative) by moving towards the test line after the interaction of the analyte and antibodies and then competing with the psilocybin molecule immobilised to the membrane. A card test according to claim 1 , characterized in that said membrane is based on nitrocellulose. An in-vitro method for detecting the presence of the psilocybin molecule, which allows the diagnosis of toxic mushrooms and mushroom toxicities, characterized in that it comprises the following process steps: adding a specific monoclonal antibody to the analyte colored by binding a color molecule on the conjugate pad; wherein said monoclonal antibody includes mouse immunoglobulin G monoclonal antibodies,
- moving the non-stationary antibodies and the analyte which may likely contain antigen together towards at least one psilocybin-containing test line,
- if the test line is single, then analyzing the test as positive.
4. An immunochromatographic card test for detecting the presence of psilocybin, which allows the diagnosis of toxic mushrooms and mushroom toxicities, which comprises
- a conjugate pad containing the antibodies specific to the psilocybin molecule, wherein said colored monoclonal antibody includes mouse immunoglobulin G monoclonal antibodies,
- an analyte for the determination of antibody-antigen interaction,
- at least one test line containing specific monoclonal antibodies and which is based on the principle that the analyte selectively binds to the specific colored antibody thereof on the conjugate pad, a complex of the analyte- antibody-color molecule moves towards the test line together with the analyte, and then a visible colored line is formed in the test line area.
5. An in-vitro method for detecting the presence of the psilocybin molecule, which allows the diagnosis of toxic mushrooms and mushroom toxicities, characterized in that it comprises the following process steps: selectively binding the analyte in the sample to the specific colored antibody thereof on the conjugate pad, wherein said colored monoclonal antibody includes mouse immunoglobulin G monoclonal antibodies,
- forming a complex of the analyte-antibody-color molecule by the analyte and antibody, and moving that complex towards the test line, binding the analyte in the complex arrived at the test line together with the sample to antibodies immobilised to the test line, and obtaining a colored visible line in the test line area.
PCT/TR2023/051529 2022-12-16 2023-12-12 A card test for the hallucinogenic psilocybin molecule that allows the diagnosis of toxic mushrooms and mushroom toxicities WO2024129040A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2022/019556 TR2022019556A2 (en) 2022-12-16 A CARD TEST FOR THE HALLUCINOGENEIC PSILOCYBIN MOLECULE THAT ALLOWS THE DIAGNOSIS OF POISONOUS MUSHROOMS AND MUSHROOM POISONING
TR2022019556 2022-12-16

Publications (1)

Publication Number Publication Date
WO2024129040A1 true WO2024129040A1 (en) 2024-06-20

Family

ID=91485574

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2023/051529 WO2024129040A1 (en) 2022-12-16 2023-12-12 A card test for the hallucinogenic psilocybin molecule that allows the diagnosis of toxic mushrooms and mushroom toxicities

Country Status (1)

Country Link
WO (1) WO2024129040A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210658A1 (en) * 2019-04-10 2020-10-15 Promega Corporation Compositions and methods for analyte detection using bioluminescence

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210658A1 (en) * 2019-04-10 2020-10-15 Promega Corporation Compositions and methods for analyte detection using bioluminescence

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEVER CANDACE S., ADAMS CATHARINE A., HNASKO ROBERT M., CHENG LUISA W., STANKER LARRY H.: "Lateral flow immunoassay (LFIA) for the detection of lethal amatoxins from mushrooms", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 15, no. 4, 17 April 2020 (2020-04-17), US , pages 1 - 18, XP093184367, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0231781 *
SUKUMARAN A ET AL.: "Development and Troubleshooting in Lateral Flow Immunochromatography Assays", INDIAN J CLIN BIOCHEM., vol. 36, no. 2, 17 April 2020 (2020-04-17), pages 208 - 212, XP037395089, [retrieved on 20210400], DOI: 10.1007/s12291-020-00887-5 *
ZHU J ET AL.: "Production of highly sensitive monoclonal antibody and development of lateral flow assays for phallotoxin detection in urine", ANAL BIOANAL CHEM., vol. 413, no. 20, 8 July 2021 (2021-07-08), pages 4979 - 4987, XP037551337, [retrieved on 20210800], DOI: 10.1007/ s 00216-021 -03457-7 *

Similar Documents

Publication Publication Date Title
DE60013789T2 (en) SPECIMEN COLLECTION AND TEST SYSTEM
DE69821229T2 (en) IMMUNOASSAY DEVICE FOR DIAGNOSTIC PURPOSES
DE60013320T2 (en) ANALYTASSAY DEVICE WITH PRE-BEER ZONE
CN102439450A (en) Assay method and device
HUE028818T2 (en) Device and method for detection of analytes
US7901623B2 (en) Lateral flow strip assay
Gao et al. Colloidal gold-based immunochromatographic test strip for rapid detection of abrin in food samples
CN101965515A (en) Methods and device for the detection of occult blood
US20150017656A1 (en) Rapid Lateral Flow Assay Method for Detecting Low Quantity Liquid or Dry Samples
WO2024129040A1 (en) A card test for the hallucinogenic psilocybin molecule that allows the diagnosis of toxic mushrooms and mushroom toxicities
DE102015218442A1 (en) Biosensor and method for the detection of germs
WO2024129041A1 (en) A card test for the diagnosis of the mushroom toxin gyromitrin and its metabolites
RU2532352C2 (en) Method of carrying out immunochromatographic analysis for serodiagnostics
CN103698531B (en) The purposes of Rv1860, Rv0173 and/or Rv1812c albumen in the phthisical product of preparation diagnostic activities
DE3874741T2 (en) IMMUNASSAY PROCEDURE.
CN103675293B (en) The purposes of Rv3872, Rv0164 and/or Rv1926c albumen in the phthisical product of preparation diagnostic activities
CN103376324A (en) Application of albumin as obesity-diabetes marker
Trowell et al. Rapid antibody-based field test to distinguish between Helicoverpa armigera (Lepidoptera: Noctuidae) and Helicoverpa punctigera (Lepidoptera: Noctuidae)
CN103149356A (en) Test paper card for testing Brucella antibody through sandwich method
EP1564556A1 (en) Method and apparatus for assaying several analytes simultaneously with an internal control
TR2022019556A2 (en) A CARD TEST FOR THE HALLUCINOGENEIC PSILOCYBIN MOLECULE THAT ALLOWS THE DIAGNOSIS OF POISONOUS MUSHROOMS AND MUSHROOM POISONING
TR2022019552A2 (en) CARD TEST FOR THE DIAGNOSIS OF FUNGAL TOXIN GYROMITRIN AND ITS METABOLITES
US20240377395A1 (en) Agglutinating agents, devices and methods for whole blood assays
CN103376326A (en) Application of vitamin D binding protein as obesity-diabetes marker
EP3489686A1 (en) Method and device for discriminating between viral and bacterial infections

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23904171

Country of ref document: EP

Kind code of ref document: A1